•  
  •  
  •  
  •  

2026-09-16 02:23:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Vikram Solar Strengthens DCR Market Position Through Domestic Cell Pact of 1 GW with Avaada Electro
  • Lemon Tree Hotels opens Keys Lite by Lemon Tree Hotels at Moga
  • Blue Dart Leadership Transition: R.S. Subramanian Appointed Managing Director as Balfour Manuel Steps Down
  • Viceroy Hotels Approves Allotment of Over 92 Lakh Equity Shares via Rights Issue
  • Union Railway Minister Shri Ashwini Vaishnaw flags off Bulk Tiles Train at Western Carriers' Gati Shakti Cargo Terminal in Morbi, Gujarat

Keywords Selected:  INE406A01037

Research

  • Aurobindo Pharma - Entry into India - a little too late?

Stock Report

  • Apitoria Pharma Pvt Ltd receives 1 observation from USFDA for Unit 2
  • Aurobindo Pharma receives USFDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg
  • Completion of US FDA Inspection at Unit-IV of Apitoria Pharma Private Limited
  • US FDA Concludes Inspection at Aurobindo Pharma's US Subsidiary with Four Observations
  • Completion of US FDA Inspection at Auro Peptides Ltd
  • Aurolife Pharma LLC receives 11 observations from USFDA for Raleigh Plant
  • Aurobindo Pharma signs non-exclusive voluntary license agreement with MSD
  • ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
  • Aurobindo Pharma USA Inc completes acquisition of Lannett Company, Inc
  • Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
  • Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company
  • Completion of US FDA Pre-Approval Inspection at Eugia Steriles Private Limited
  • Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Ltd, Pashamylaram as OAI
  • Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Aurobindo Pharma Inaugurates TheraNym - Pioneering India's Large-Scale Biologics Contract Manufacturing Facility
  • Classification of Unit-I of Eugia Pharma Specialities Ltd, Shameerpet as OAI
  • CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar
  • Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
  • Aurobindo Pharma receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
  • CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG
  • Classification of Unit-V of Apitoria Pharma Ltd as VAI by the US FDA

Latest Post

  • Vikram Solar Strengthens DCR Market Position Through Domestic Cell Pact of 1 GW with Avaada Electro
  • Lemon Tree Hotels opens Keys Lite by Lemon Tree Hotels at Moga
  • Blue Dart Leadership Transition: R.S. Subramanian Appointed Managing Director as Balfour Manuel Steps Down
  • Viceroy Hotels Approves Allotment of Over 92 Lakh Equity Shares via Rights Issue
  • Union Railway Minister Shri Ashwini Vaishnaw flags off Bulk Tiles Train at Western Carriers' Gati Shakti Cargo Terminal in Morbi, Gujarat


Announcement

To Advertise in our website please e-mail us at [email protected]
Companies can send their Press Releases to [email protected]

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: [email protected]
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025